IR-780-Albumin-Based Nanocarriers Promote Tumor Regression Not only from Phototherapy but Also by a Nonirradiation Mechanism

Gustavo Capistrano, Ailton A. Sousa-Junior, Roosevelt A. Silva, Francyelli Mello-Andrade, Emilio R. Cintra, Sônia Santos, Allancer D. Nunes, Raisa M. Lima, Nicholas Zufelato, André S. Oliveira, Maristela Pereira, Carlos H. Castro, Eliana M. Lima, Clever G. Cardoso, Elisângela Silveira-Lacerda, Sebastião A. Mendanha, Andris F. Bakuzis

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

IR-780 iodide is a fluorescent dye with optical properties in the near-infrared region that has applications in tumor detection and photothermal/photodynamic therapy. This multifunctional effect led to the development of theranostic nanoparticles with both IR-780 and chemotherapeutic drugs such as docetaxel, doxorubicin, and lonidamine. In this work, we developed two albumin-based nanoparticles containing near-infrared IR-780 iodide multifunctional dyes, one of them possessing a magnetic core. Molecular docking with AutoDock Vina studies showed that IR-780 binds to bovine serum albumin (BSA) with greater stability at a higher temperature, allowing the protein binding pocket to better fit this dye. The theoretical analysis corroborates the experimental protocols, where an enhancement of IR-780 was found coupled to BSA at 60 °C, even 30 days after preparation, in comparison to 30 °C. In vitro assays monitoring the viability of Ehrlich ascites carcinoma cells revealed the importance of the inorganic magnetic core on the nanocarrier photothermal-cytotoxic effect. Fluorescence molecular tomography measurements of Ehrlich tumor-bearing Swiss mice revealed the biodistribution of the nanocarriers, with marked accumulation in the tumor tissue (≈3% ID). The histopathological analysis demonstrated strong increase in tumoral necrosis areas after 24 and 72 h after treatment, indicating tumor regression. Tumor regression analysis of nonirradiated animals indicate a IR-780 dose-dependent antitumoral effect with survival rates higher than 70% (animals monitored up to 600 days). Furthermore, an in vivo photothermal therapy procedure was performed and tumor regression was also verified. These results show a novel insight for the biomedical application of IR-780-albumin-based nanocarriers, namely cancer therapy, not only by photoinduced therapy but also by a nonirradiation mechanism. Safety studies (acute oral toxicity, cardiovascular evaluation, and histopathological analysis) suggest potential for clinical translation.

Original languageEnglish (US)
Pages (from-to)4523-4538
Number of pages16
JournalACS Biomaterials Science and Engineering
Volume6
Issue number8
DOIs
StatePublished - Aug 10 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
Copyright © 2020 American Chemical Society.

Keywords

  • cancer nanomedicine
  • drug delivery
  • iron oxide nanoparticles
  • photothermal therapy
  • protein-based nanoparticles

Fingerprint

Dive into the research topics of 'IR-780-Albumin-Based Nanocarriers Promote Tumor Regression Not only from Phototherapy but Also by a Nonirradiation Mechanism'. Together they form a unique fingerprint.

Cite this